Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 161.43M | 124.90M | 93.46M | 67.88M | 56.82M |
Gross Profit | 122.24M | 92.36M | 92.94M | 46.66M | 56.42M |
EBITDA | 120.69M | 91.69M | 69.64M | 49.53M | 37.70M |
Net Income | 82.79M | 60.65M | 44.44M | 30.85M | 23.08M |
Balance Sheet | |||||
Total Assets | 257.43M | 202.13M | 157.05M | 125.57M | 95.64M |
Cash, Cash Equivalents and Short-Term Investments | 154.89M | 121.50M | 90.55M | 61.82M | 43.41M |
Total Debt | 2.07M | 1.85M | 2.28M | 2.62M | 2.28M |
Total Liabilities | 69.70M | 63.36M | 55.32M | 43.89M | 35.46M |
Stockholders Equity | 187.73M | 138.78M | 101.73M | 81.68M | 60.18M |
Cash Flow | |||||
Free Cash Flow | 80.08M | 58.33M | 53.20M | 31.33M | 23.72M |
Operating Cash Flow | 86.78M | 64.77M | 62.23M | 39.02M | 31.59M |
Investing Cash Flow | -78.07M | -9.79M | -17.56M | -27.40M | -7.87M |
Financing Cash Flow | -39.84M | -27.53M | -23.31M | -14.05M | -12.31M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | $33.39B | 339.72 | 52.66% | 0.15% | 29.87% | 40.97% | |
60 Neutral | HK$17.55B | 4.98 | -4.95% | 3.61% | 9.71% | -38.85% | |
― | $56.60M | ― | -9.88% | ― | ― | ― | |
60 Neutral | AU$17.47M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
56 Neutral | AU$40.64M | 110.00 | -8.34% | ― | -5.27% | 50.29% | |
55 Neutral | AU$74.19M | ― | -457.46% | ― | 21.93% | 10.34% | |
53 Neutral | AU$147.72M | ― | -5.63% | ― | -11.96% | 7.50% |
Pro Medicus Limited has announced a financing agreement with 4DMedical to support the development and commercialization of 4DMedical’s lung function imaging and analysis software. This strategic move is expected to enhance Pro Medicus’s position in the health imaging industry and potentially expand its market reach, benefiting stakeholders through improved product offerings.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
4DMedical Limited has secured a $10 million strategic investment from Pro Medicus, a leading medical imaging software company, to accelerate its commercial pipeline and advance its CT:VQ™ product towards regulatory clearance in the U.S. This investment, structured as a hybrid debt and equity loan, provides growth capital without diluting shares if 4DMedical’s share price remains stable, while aligning interests with Pro Medicus if the share price rises. The agreement also allows Pro Medicus to distribute 4DMedical products, potentially enhancing their market reach and operational capabilities.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has announced that it will release its full year results for FY25 on August 14, 2025. The company will also hold a webcast conference call on the same day to discuss the results, indicating a transparent approach to stakeholder communication and potential implications for its market positioning.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has secured a significant A$170 million, 10-year contract with UCHealth, a Colorado-based healthcare system, to implement its Visage 7 Enterprise Imaging Platform across UCHealth’s network. This strategic move enhances Pro Medicus’s position in the North American market by replacing UCHealth’s legacy systems with a unified, cloud-based solution, potentially setting a new standard in healthcare imaging technology.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited’s U.S. subsidiary, Visage Imaging, Inc., has secured a 5-year contract renewal worth at least A$20 million with the Franciscan Missionaries of Our Lady Health System. The agreement includes the Visage 7 Viewer and a new Visage 7 Open Archive, both to be implemented in the cloud with a transaction-based model. This move highlights Pro Medicus’s strategic focus on transitioning clients to cloud-based solutions, potentially enhancing its market position and offering growth opportunities.
The most recent analyst rating on (AU:PME) stock is a Hold with a A$130.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
Pro Medicus Limited has secured a AUD $20 million, 5-year contract with University of Iowa Health Care to implement its Visage 7 Enterprise Imaging Platform across the institution. This agreement will replace the legacy PACS system with a cloud-based solution, enhancing diagnostic imaging and integrating with electronic health records. The rollout is set to begin immediately, with completion targeted for Q4 2025, marking a significant step in Pro Medicus’s expansion in the healthcare IT sector.